MDxHealth SA (NASDAQ: MDXH)

MDxHealth SA is a commercial stage precision diagnostics company that provides noninvasive, clinically actionable, and cost effective urologic solutions to improve patient care. Its core menu includes the Confirm mdx test for prostate cancer, the GPS mdx test for genomic profiling, and the Exo mdx test for urine based risk assessment. Following the acquisition of Exosome Diagnostics the company added the Exo mdx test to its portfolio offering a non invasive urine based option for men with elevated PSA levels. The company also markets the Resolve mdx test which delivers rapid pathogen identification and personalized antibiotic susceptibility results for urinary tract infections. These tests are designed to help physicians avoid unnecessary biopsies and guide appropriate treatment decisions while reducing patient anxiety and healthcare costs.

The company generates revenue primarily through the sale of its diagnostic tests including Confirm mdx, GPS mdx, Exo mdx, and Resolve mdx to urology clinics and pathology laboratories. It maintains a direct sales force in the United States that focuses on building relationships with urology practices and laboratory partners. The company also evaluates distribution partners in select international markets to expand the availability of its tests beyond North America. Revenue is recognized when the test results are delivered and the associated service is completed.

MDxHealth SA holds a niche position in the urology diagnostics market where it competes with larger firms such as Labcorp which offers the 4Kscore test, Lynx Dx which offers the MyProstateScore 2.0 test, and Beckman Coulter which offers the phi score test. Its competitive advantages stem from Medicare reimbursement for its tests, inclusion in National Comprehensive Cancer Network guidelines for each of its core assays, proprietary biomarker technology, and its CLIA accredited CAP certified laboratory network. The company has built a substantial intellectual property portfolio with over 18 patent families covering its epigenetic and molecular assays. This focus on innovation and commercial execution supports its goal of becoming a trusted partner in urology care.

MDxHealth SA serves more than 7,000 urologists who have ordered over 500,000 of its tests to date. Its customers include urology clinics, community based practices, and pathology laboratories that rely on its noninvasive and tissue based diagnostic solutions. The company directs its sales efforts toward major community urology centers that have high patient volumes and seek to improve diagnostic accuracy. By providing actionable results throughout the patient journey from initial screening to treatment selection MDxHealth aims to support physicians and enhance the quality of care.